Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller; Andrew Blauvelt; Weily Soong; Shinichi Imafuku; Chih Ho Hong; Marie L.A. Schuttelaar; Petra Amoudruz; Azra Kurbasic; Lise Soldbro; Katja Lophaven; Michael Cork; Anthony Bewley; Eric L. Simpson

doi:10.25251/skin.6.supp.s29

Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih Ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson

Public Health Research

Onderzoeksoutput › Academic › peer review

4 Citaten (Scopus)

20 Downloads (Pure)

Originele taal-2	English
Pagina's (van-tot)	s29
Aantal pagina's	1
Tijdschrift	SKIN: Journal of Cutaneous Medicine
Volume	6
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.25251/skin.6.supp.s29
Status	Published - 4-mrt.-2022

Toegang tot document

10.25251/skin.6.supp.s29Licentie: CC BY

Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitisFinal publisher's version, 201 KBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

Paller, A., Blauvelt, A., Soong, W., Imafuku, S., Hong, C. H., Schuttelaar, M. L. A., Amoudruz, P., Kurbasic, A., Soldbro, L., Lophaven, K., Cork, M., Bewley, A., & Simpson, E. L. (2022). Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN: Journal of Cutaneous Medicine, 6(2), s29. https://doi.org/10.25251/skin.6.supp.s29

@article{5e34b1c351624149b0cc53139d5de27a,

title = "Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial",

author = "Amy Paller and Andrew Blauvelt and Weily Soong and Shinichi Imafuku and Hong, {Chih Ho} and Schuttelaar, {Marie L.A.} and Petra Amoudruz and Azra Kurbasic and Lise Soldbro and Katja Lophaven and Michael Cork and Anthony Bewley and Simpson, {Eric L.}",

note = "Funding Information: The ECZTRA 6 clinical trial was sponsored by LEO Pharma A/S, Ballerup, Denmark Medical writing and editorial support from Alphabet Health by Clair Geary, PhD, was funded by LEO Pharma A/S, Ballerup, Denmark This work was previously presented at Fall Clinical Dermatology Conference, Oct 21-24, 2021",

year = "2022",

month = mar,

day = "4",

doi = "10.25251/skin.6.supp.s29",

language = "English",

volume = "6",

pages = "s29",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

number = "2",

}

Paller, A, Blauvelt, A, Soong, W, Imafuku, S, Hong, CH, Schuttelaar, MLA, Amoudruz, P, Kurbasic, A, Soldbro, L, Lophaven, K, Cork, M, Bewley, A & Simpson, EL 2022, 'Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial', SKIN: Journal of Cutaneous Medicine, vol. 6, nr. 2, blz. s29. https://doi.org/10.25251/skin.6.supp.s29

TY - JOUR

T1 - Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis

T2 - results of the phase 3 ECZTRA 6 trial

AU - Paller, Amy

AU - Blauvelt, Andrew

AU - Soong, Weily

AU - Imafuku, Shinichi

AU - Hong, Chih Ho

AU - Schuttelaar, Marie L.A.

AU - Amoudruz, Petra

AU - Kurbasic, Azra

AU - Soldbro, Lise

AU - Lophaven, Katja

AU - Cork, Michael

AU - Bewley, Anthony

AU - Simpson, Eric L.

N1 - Funding Information: The ECZTRA 6 clinical trial was sponsored by LEO Pharma A/S, Ballerup, Denmark Medical writing and editorial support from Alphabet Health by Clair Geary, PhD, was funded by LEO Pharma A/S, Ballerup, Denmark This work was previously presented at Fall Clinical Dermatology Conference, Oct 21-24, 2021

PY - 2022/3/4

Y1 - 2022/3/4

U2 - 10.25251/skin.6.supp.s29

DO - 10.25251/skin.6.supp.s29

M3 - Article

AN - SCOPUS:85127320548

VL - 6

SP - s29

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

SN - 2574-1624

IS - 2

ER -